The purpose of this study is to compare Selumetinib and Olaparib vs Selumetinib alone. You must be diagnosed with recurrent or persisent Ovarian or Endometiral cancer. Your cancer must have a RAS pathway mutation.
Contact phoneTera Williams | 517.364.2910
Principal investigatorDr. Gordan Srkalovic, MD, PhD
Trial SubCategoryOvarian & Endometrial